Fig. 5: Comparison of OMICmAge and DNAmEMRAge to previously established aging biomarkers.
From: OMICmAge quantifies biological age by integrating multi-omics with electronic medical records
a, Intersection of predictive CpG sites included in the previously published epigenetic clocks, DNAmEMRAge and OMICmAge. The horizontal bars represent the total number of CpG sites included in each epigenetic aging biomarker. The vertical bars represent the number of unique or shared CpG sites between clocks. PhenoAge refers to the DNAm version. b, Horizontal error bar plot of ORs/HRs of each methylation biomarker and chronological age to aging-related diseases in the testing set of the MGB-ABC cohort. The ratios and 95% CIs are based on a 1-s.d. change around the estimated mean values from the statistical models. The number of cases (n) and sample sizes (N) for each phenotype are as follows. Incident cases: all-cause mortality, N = 662 (n = 83); stroke, N = 616 (n = 45); type 2 diabetes, N = 428 (n = 52); COPD, N = 485 (n = 39); depression, N = 361 (n = 52); CVD (excluding stroke), N = 287 (n = 82); cancer, N = 524 (n = 68). Prevalent cases: The total sample size for prevalent diseases is 689, with the following case numbers; stroke, n = 73; type 2 diabetes, n = 261; COPD, n = 204; depression, n = 328; CVD (excluding stroke), n = 402; cancer, n = 162. c, Receiver operating characteristic curves comparing 5-year and 10-year survival predictions based on DNAm aging biomarkers and chronological age within the MGB-ABC cohort. Individual lines denote specific biomarkers.
